House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Infectious diseases

Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use

NICE · 2015 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE guideline NG15 sets out system-level and prescriber-level recommendations to support effective antimicrobial use across all health and social care settings. It covers stewardship programmes and teams, interventions, communication and culture, and laboratory reporting. It also covers individual prescribing decisions: microbiological sampling, patient discussion, back-up prescribing, documentation, repeat prescriptions and intravenous review. A final set covers how local decision-making groups introduce, restrict and monitor new antimicrobials. Much of the guidance is advisory ('consider'). Some actions are directed at commissioners and organisations rather than individual clinicians.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Stewardship programmes and teams

  • Commissioners should ensure that stewardship operates across all care settings as part of a stewardship programme. The programme should be established taking account of the resources needed to support stewardship across all settings. [1]
  • Elements organisations can consider including in a programme include monitoring and evaluating prescribing in relation to local resistance patterns. They also include regular feedback to individual prescribers on their own prescribing and on safety incidents. Such incidents include admissions for potentially avoidable life-threatening infections, Clostridium difficile infections, and adverse reactions such as anaphylaxis. [1]
  • Consider systems that give individual prescribers and prescribing leads regular updates, at least every year. Updates would cover their prescribing benchmarked against local and national rates and trends, local and national resistance trends, and antimicrobial-related safety incidents. [1]
  • Consider systems that identify and review whether hospital admissions of patients with potentially avoidable infections are linked to earlier prescribing decisions. Examples include Escherichia coli bacteraemias, mastoiditis, pyelonephritis, empyema, quinsy and brain abscess. [1]
  • Organisations setting up stewardship teams should ensure the team has core members, including an antimicrobial pharmacist and a medical microbiologist. Teams can co-opt others depending on the care setting. Teams should be supported to review prescribing and resistance data and feed it back to prescribers in all settings. They should also be supported to advise prescribers whose prescribing outside local guidelines is not justified. [1]
  • Involve lead practitioners in processes for developing, reviewing, updating and implementing local antimicrobial guidelines. These guidelines should be in line with national guidance and informed by local prescribing data and resistance patterns. Raise awareness of current local guidelines among all prescribers, and provide updates when the guidelines change. [1]

Stewardship interventions, systems and laboratory reporting

  • Several interventions can be considered: - stewardship-team review of the reasons for increasing, very high or very low prescribing volumes - promotion of antimicrobials recommended in local (where available) or national guidelines - IT or decision support systems - practitioner education such as academic detailing, clinical education or educational outreach. [1]
  • Consider IT or decision support that helps prescribers decide whether to prescribe an antimicrobial at all. It can also help them decide whether alternatives to immediate prescribing, such as back-up prescribing or early review if concerns arise, may be appropriate. [1]
  • Consider systems that pass on three pieces of information when care transfers to another setting. These are current or recent antimicrobial use, when the current course should be reviewed, and whom the patient should contact, and when, about infection concerns. [1]
  • Consider prioritising resistance monitoring to support stewardship. Also consider supplying pack sizes that match local (where available) and national course lengths. Stewardship interventions can be evaluated by reviewing prescribing and resistance rates and trends. [1]
  • Laboratory testing, and the order in which organism susceptibilities are reported, should align with three things. These are national and local treatment guidelines, local formulary choices, and the priorities of medicines management and stewardship teams. [1]

Communication and culture

  • Encourage and support prescribers to prescribe antimicrobials only when clinically appropriate. Encourage health and social care practitioners across all care settings to work together to support stewardship. This includes referring appropriately between services without raising expectations that antimicrobials will later be prescribed. [1]
  • Consider local peer review of prescribing. Encourage an open culture in which colleagues can question prescribing that departs from local or national guidelines with no reason documented. Encourage senior professionals to promote stewardship within their teams. [1]

Prescribing decisions

  • Prescribers should follow local (where available) or national guidelines on the shortest effective course, the most appropriate dose and route of administration. When deciding whether to prescribe, they should take into account the resistance risk for the individual patient and the population. [1]
  • When prescribing any antimicrobial, carry out a clinical assessment and record the diagnosis, including symptoms. When an antimicrobial is a treatment option, record the reason for prescribing or not prescribing. Also record the care plan discussed with the patient or carer, including planned treatment duration. Record the reasons for any prescribing outside local or national guidelines. [1]
  • For hospital patients with suspected infection, take microbiological samples before prescribing and review the prescription when results are available. For primary care patients with recurrent or persistent infections, consider sampling when prescribing and review the prescription when the results are available. [1]
  • For patients with non-severe infections, consider sampling before deciding whether to prescribe, provided it is safe to withhold treatment until results are available. Consider point-of-care testing in primary care for suspected lower respiratory tract infection, as described in NICE's guideline on pneumonia in adults. [1]
  • Prescribers should take time to discuss several topics with the patient and/or their family members or carers (as appropriate): - the likely nature of the condition - why an antimicrobial may not be the best option - alternatives to prescribing an antimicrobial - their views on antimicrobials, taking into account their priorities or concerns for their current illness and whether they want or expect an antimicrobial. [1]
  • The same discussion with the patient and/or their family members or carers (as appropriate) should also cover: - the benefits and harms of immediate prescribing - what to do if the condition deteriorates (safety netting) or they have problems as a result of treatment - whether they need written information about their medicines and any possible outcomes. [1]
  • Do not issue an immediate prescription for a likely self-limiting condition. If immediate prescribing is not the most appropriate option, discuss alternatives. These include over-the-counter self-care, back-up (delayed) prescribing, or non-drug measures such as draining the infection site. [1]
  • Once a decision to prescribe is made, take several factors into account. These are interactions with other medicines, food or drink, and other illnesses, such as renal impairment needing dose adjustment. They also include any drug allergies, which should be documented in the record, and the risk of selecting organisms causing healthcare-associated infections, such as C. difficile. [1]
  • Do not issue repeat antimicrobial prescriptions unless they are needed for a particular clinical condition or indication. Avoid repeats beyond 6 months without review. Ensure adequate monitoring to reduce adverse reactions and to check whether continuing is really needed. [1]

Intravenous antimicrobials

  • When an empirical IV antimicrobial is needed for a suspected infection without a confirmed diagnosis, use the agreed local formulary in line with local (where available) or national guidelines. Consider reviewing IV prescriptions at 48–72 hours in all settings, including community and outpatient services. Use treatment response and microbiological results to decide whether to continue and whether an oral switch is possible. [1]

New antimicrobials

  • Consider reviewing national horizon scanning. Also consider using an existing local decision-making group, such as a drug and therapeutics committee, to consider introducing new antimicrobials locally. Ensure local formularies, prescribing guidelines and care pathways are updated once new agents are approved. [1]
  • When evaluating a new antimicrobial for local use and formulary inclusion, factors to take into account include: - its clinical effectiveness - the population and the organisms or conditions it will be used for - dose, frequency, formulation and route - interactions, contraindications or cautions - whether use should be restricted and how it would be monitored. [1]
  • Local decision-making groups should assess the benefits and risks of restricting access to a new antimicrobial. If access is restricted, document the rationale and nature of the restriction, make this publicly available, and review it regularly to confirm it is still appropriate. [1]
  • After a new antimicrobial is approved for local use, organisations should consider ongoing monitoring. This could include antimicrobial use reviews and review of clinical outcomes such as treatment response. [1]

Limitations and use

  • The guideline addresses systems, processes and general prescribing behaviour. It does not give condition-specific antimicrobial choices, doses or course lengths, and defers these to local or national guidelines.
  • Research recommendations and later rationale and update sections were not included in the reviewed text.
  • The implementation ('getting started') section describes possible actions and is not formal recommendation text.
  • Many recommendations are advisory ('consider'), and several are directed at commissioners, organisations or local decision-making groups rather than individual clinicians.
  • The guidance was written for the UK NHS context. It references UK bodies and resources such as the BNF, MHRA and TARGET.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
18 August 2015
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Stewardship programmes and teams
  • Stewardship interventions, systems and laboratory reporting
  • Communication and culture
  • Prescribing decisions
  • Intravenous antimicrobials
  • New antimicrobials
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House